FDA Wants to Ban NAC Now That It Combats COVID-19
September 4, 2020
NAC Inhibits Viral Replication
The idea that NAC can be helpful against viral infections is not new. Previous studies have found it reduces viral replication of certain viruses, including the influenza virus. As reported by board-certified nutritionist Joseph Debé:6
“NAC was tested in a 6-month human study7 of influenza. It was a randomized, double-blind, placebo controlled trial involving 262 people. Half of the subjects received 600 mg of NAC, the other half received placebo, twice daily for 6 months.
******************************************************************
n this MedCram video, Seheult reviews the abnormal blood clotting aspects of COVID-19. Interestingly, NAC addresses this problem too, as several studies22,23,24,25 have confirmed it counteracts hypercoagulation and reduces the risk of blood clots and stroke.
As noted in one of these studies,26 “NAC has anticoagulant and platelet-inhibiting properties.” It also has potent thrombolytic effects, meaning it breaks down blood clots that have already formed.27 According to another study,28 NAC protects against stroke in part by enhancing GSH and correcting antioxidant levels.
NAC was found to improve immune function and reduce the severity of influenza infections. Both groups had similar infection rates with A/H1N1 virus influenza. However, whereas 79% of placebo-treated people had symptomatic infections, only 25% of subjects treated with NAC were symptomatic!
There were a total of 99 flu-like episodes (symptomatic periods) that occurred in 62 people in the placebo group over the 6 month study. 48% of these were classified as mild, 47% were moderate, and 6% were severe.
In the NAC group, 46 flu-like episodes occurred in 37 subjects. 72% of these were mild, 26% were moderate and only 2% severe. There were many fewer days of being bedridden in the NAC group.”
